Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901

Cancers (Basel). 2025 May 2;17(9):1551. doi: 10.3390/cancers17091551.

¹ Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai 981-0914, Japan.
² Department of Internal Medicine, Matsuzono Daini Hospital, Morioka 020-0103, Japan.
³ Department of Respiratory Medicine, Hirosaki University Hospital, Hirosaki 036-8563, Japan.
⁴ Department of Respiratory Medicine, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan.
⁵ Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
⁶ Department of Respiratory Medicine, Yamanashi Prefectural Central Hospital, Kofu 400-8506, Japan.
⁷ Department of Thoracic Surgery, Omagari Kosei Medical Center, Daisen 014-0027, Japan.
⁸ First Department of Internal Medicine, Toyama University Hospital, Toyama 930-0194, Japan.
⁹ Department of Respiratory Medicine, Iwate Medical University Hospital, Iwate 028-3695, Japan.

Abstract

The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC) [...].

Keywords: atezolizumab; immune-checkpoint inhibitor; nivolumab; non-small cell lung cancer; pembrolizumab; retreatment.